Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being ...